Aminoverse B.V. is a biotechnology Contract Research Organisation (CRO) that catalyses innovation in enzyme research and development specifically for the pharmaceutical industry. Founded in 2020, the company leverages over 35 years of experience to offer a unique combination of enzyme wet lab expertise and advanced computational biology. Aminoverse facilitates the acceleration and de-risking of enzyme innovation, from target reactions to tailored enzymes, effectively blending traditional methods with state-of-the-art artificial intelligence solutions.

Services include:
- APIs (Active Pharmaceutical Ingredients)
- Contract Development and Manufacturing (CDMO)
- Enzyme research and development
- In silico design services

Aminoverse B.V. is dedicated to enhancing the pharmaceutical sector's research and development capabilities by providing comprehensive support in enzyme innovation. For more information, please visit aminoverse.com.